Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group studyShaji Kumar, John Crowley, J. Haessler et al.|Leukemia|2011Cited by 721
Triplet Therapy, Transplantation, and Maintenance until Progression in MyelomaPaul G. Richardson, Irene M. Ghobrial, Susanna Jacobus et al.|New England Journal of Medicine|2022Cited by 457
A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or In Combination with Low-Dose Dexamethasone In Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and BortezomibPaul G. Richardson, Kenneth C. Anderson, Rachid Baz et al.|Blood|2010Cited by 7